Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
13/02/2024 15:15
Feb 13 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS COMMENCES PATIENT DOSING IN PHASE 1
CLINICAL TRIAL OF OLX75016 FOR MASH
* OLX75016'S SAFETY AND TOLERABILITY TO BE EVALUATED
* DEMONSTRATED ENHANCED WEIGHT LOSS EFFECTS WHEN
ADMINISTERED WITH
GLP-1 OBESITY DRUG
* AUSTRALIA PHASE 1 CLINICAL TRIALS ON 70 HEALTHY + NAFLD
PARTICIPANTS
* ADDITIONAL NONCLINICAL STUDY ONGOING TO IDENTIFY
WEIGHT-MANAGING
EFFICACY OF OLX75016-DUAL GIP/GLP-1 RECEPTOR AGONISTS COMBI
TREATMENT
Source text for Eikon: ID:nBw3DR7sLa
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment